Research shows a relationship between increased SARS-CoV-2 seroreactivity and antimalarial humoral immunity

In a recent study published in the US Centers for Disease Control and Prevention (CDC) emerging infectious diseases In the journal, researchers investigate the cross-reactivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with pre-pandemic malaria-exposed sera samples collected from Cambodia. Stady: SARS-CoV-2 cross-reactivity in pre-pandemic serum of malaria-infected subjects in rural areas, Cambodia. Image … Read more

New oral pill for COVID-19 home treatment

The continued emergence of novel and potentially threatened SARS-CoV-2 variants, the latest of which is the highly pathogenic Omicron variant (VOC), is evidence that the coronavirus 2019 (COVID-19) pandemic is far from over, although The massive spread of vaccines. As cases and hospitalizations continue to rise in many countries, new treatments are being sought to … Read more

Ad5-nCoV vaccine safe and effective against symptomatic, severe COVID-19, trials shows

Single dose of Ad5-nCoV (Convidecia), a COVID-19 vaccine developed in China, is 57.5% effective against symptoms of COVID-19 and 91.7% effective against severe COVID-19 disease onset 28 days after vaccination, according to a randomized phase 3 Censored trial published in scalpel. The report indicates that Ad5-nCoV is safe, with no serious vaccine-related adverse events or … Read more

LIVE-AIR trial demonstrates efficacy of Lenzilumab for treatment of COVID patients with decreased oxygen saturation

The novel coronavirus 2019 (COVID-19) pandemic was caused by a new coronavirus, i.e., severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The RNA virus causes mild to severe symptoms and has a high transmission rate. In severe infection, patients often have a highly inflammatory response, which has been associated with morbidity and mortality due to COVID-19 disease. … Read more